Drug Profile
Research programme: glutathione peroxidase mimetics - Synvista Therapeutics/GT Biopharma
Alternative Names: Organoselenium compounds - Synvista Therapeutics/GT BiopharmaLatest Information Update: 10 Aug 2017
Price :
$50
*
At a glance
- Originator OXIS International
- Developer Synvista Therapeutics
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 07 Aug 2017 Oxis International is now called GT Biopharma
- 24 Jul 2007 Alteon is now called Synvista Therapeutics
- 12 Apr 2007 Preclinical trials in Inflammation in USA (IV)